I have a follow-up question for you, Mr. Outterson.
You mentioned that Canada is a small market for AMR drugs, but there are smaller countries in Europe. Are you implying that they're more profitable? Is Canada's being a smaller market due to the lack of funding from Canada or possibly due also to the bureaucracy from within Canada?